Search Results - "Pourrahmat, M.M."

HPR33 Follow the Money: Reporting Public Contributions and Incentives on Research and Development Programs for Agenzia Italiana Del Farmaco (AIFA; ITALIAN MEDICINES AGENCY) by Pourrahmat, M.M., Maposa, P., del Aguila, M., Fazeli, M.S.

Get full text

P2 Economic Burden and Healthcare Resource Utilization in Sjögren's Disease: A Systematic Literature Review by Choi, J., Christodoulou, A., Sreih, A., Hofer, K., Pourrahmat, M.M., Fazeli, M.S., Fisher, B.A.

Get full text

PCR101 Patient-Centric-Approach and Personalized Clinical Trials to Increase Patients Participation in Drug Development: Insight from a Targeted Literature Review (TLR) by Collet, J.P., Shouman, W., Hofer, K., Pourrahmat, M.M., Maposa, P., Fazeli, M.S.

Get full text

MT2 HBA1C Reduction with Digital Health Devices in Type 2 Diabetes (T2DM): A Meta-Analysis of Randomized Controlled Trials by Lee, F., Han-Burgess, E., Kennedy, A., Serafini, P., Pourrahmat, M.M., Breznen, B.

Get full text

P49 Evaluation of Surrogate Endpoints (SES) for Previously Untreated Unresectable or Metastatic Melanoma (MMEL): Analyses from a Longitudinal Electronic Health Record Database in the United States (US) by Leung, L., Mohr, P., Serafini, P., Kanters, S., Pourrahmat, M.M., Moshyk, A., Srinivasan, S., Kurt, M.

Get full text

PMS9 PLACEBO EFFECT IN KNEE OSTEOARTHRITIS: A TARGETED LITERATURE REVIEW ON THE CHALLENGES, HYPOTHESES, AND POTENTIAL SOLUTIONS by Hofer, K., Lin, M., Pourrahmat, M.M., Fazeli, M.S.

Get full text

CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs) by Leung, L., Kirkwood, J., Srinivasan, S., Dyer, M., Qian, A., Pourrahmat, M.M., Kasireddy, E., May, J.R., Moshyk, A., Kurt, M.

Get full text

CO205 Evaluating Disease-Free Survival (DFS) As a Surrogate Endpoint (SE) for Overall Survival (OS) in Muscle-Invasive Urothelial Carcinoma (MIUC): An Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare Data by Leung, L., Kanters, S., Pourrahmat, M.M., Friedman, H.S., Navaratnam, P., Reardon, G., Patel, M.Y., Teitsson, S., Kurt, M., Lotan, Y.

Get full text

PCN7 Analysis of Individual-Level Association of Progression-Free Survival (PFS) and Time to Treatment Failure (TTF) with Overall Survival (OS) for Previously Untreated Advanced Renal Cell Carcinoma Patients in the CheckMate 214 Trial by Siliman, G., Kanters, S., Fazeli, M.S., Pourrahmat, M.M., Ejzykowicz, F., Kurt, M.

Get full text

PCN309 HEALTH STATE UTILITY VALUES ACROSS CANCER TYPES AND STAGES: A SYSTEMATIC LITERATURE REVIEW by Pourrahmat, M.M., Kansal, A.R., Chung, K.C., Hux, M., Howarth, A., Fazeli, M.S.

Get full text